Publicaciones en colaboración con investigadores/as de Montreal Heart Institute (28)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis

    Cardiovascular Diabetology, Vol. 22, Núm. 1

2019

  1. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study

    Journal of the American College of Cardiology, Vol. 73, Núm. 6, pp. 629-638

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2015

  1. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    PLoS ONE, Vol. 10, Núm. 4

2013

  1. Relationship of Quality of Life With Procedural Success of Atrial Fibrillation (AF) Ablation and Postablation AF Burden: Substudy of the STAR AF Randomized Trial

    Canadian Journal of Cardiology, Vol. 29, Núm. 10, pp. 1211-1217

2012

  1. Incidence and significance of early recurrences associated with different ablation strategies for AF: A STAR-AF substudy

    Journal of Cardiovascular Electrophysiology, Vol. 23, Núm. 12, pp. 1295-1301

  2. Vorapaxar in the secondary prevention of atherothrombotic events

    New England Journal of Medicine, Vol. 366, Núm. 15, pp. 1404-1413

2011

  1. Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: A clinical-experimental correlation

    Heart Rhythm, Vol. 8, Núm. 9, pp. 1426-1433

2010

  1. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial

    The Lancet, Vol. 376, Núm. 9748, pp. 1233-1243

  2. Mechanisms by which adenosine restores conduction in dormant canine pulmonary veins

    Circulation, Vol. 121, Núm. 8, pp. 963-972

  3. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): A randomized, multicentre, international trial

    European Heart Journal, Vol. 31, Núm. 11, pp. 1344-1356

2009

  1. Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial

    JACC: Cardiovascular Interventions, Vol. 2, Núm. 11, pp. 1083-1091

  2. The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes

    American Heart Journal, Vol. 158, Núm. 2, pp. 201.e5

2008

  1. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the STEEPLE trial

    European Heart Journal, Vol. 29, Núm. 4, pp. 462-471

2007

  1. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: Benefit and harm in different age subgroups

    Heart, Vol. 93, Núm. 4, pp. 450-455

  2. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2006

  1. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention

    New England Journal of Medicine, Vol. 355, Núm. 10, pp. 1006-1017

  2. Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes

    European Heart Journal, Vol. 27, Núm. 24, pp. 2956-2961

2005

  1. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with Tolvaptan (EVEREST)

    Journal of Cardiac Failure, Vol. 11, Núm. 4, pp. 260-269